Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SULFAPYRIDINE vs CETAMIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sulfapyridine is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, blocking folate synthesis and thereby nucleic acid production. It also has anti-inflammatory and immunomodulatory effects in dermatologic conditions through unknown mechanisms.
CETAMIDE is an antimicrobial combination of sulfadiazine (a sulfonamide) and trimethoprim. Sulfonamides inhibit dihydropteroate synthase, blocking folate synthesis; trimethoprim inhibits dihydrofolate reductase, producing sequential blockade of folic acid metabolism.
FDA-approved for dermatitis herpetiformis,Off-label: rheumatoid arthritis, inflammatory bowel disease, and other inflammatory dermatoses
Urinary tract infections,Acute otitis media,Shigellosis,Pneumocystis jirovecii pneumonia,Traveler's diarrhea (off-label)
500 mg orally four times daily for initial treatment of dermatitis herpetiformis; maintenance dose 500 mg daily to 1.5 g daily in divided doses.
500 mg orally every 6 hours; maximum 4 g per day.
Terminal elimination half-life: 6–10 hours (prolonged in renal impairment or slow acetylators); clinical context: requires dosing adjustment in renal insufficiency.
6-8 hours; prolonged (up to 30 hours) in severe renal impairment (Cr Cl <30 m L/min).
Primarily hepatic via N-acetylation (N-acetyltransferase 2, NAT2) and glucuronidation; also undergoes hydroxylation. Excreted renally.
Sulfadiazine is metabolized via acetylation (N-acetyltransferase) and glucuronidation; trimethoprim is metabolized by oxidative pathways (N-oxidation, N-demethylation) and conjugated with glucuronic acid.
Renal: approximately 70–80% (30% as unchanged drug, remainder as metabolites, primarily N4-acetylsulfapyridine); biliary/fecal: minor (<5%).
Primarily renal (85-90%) as unchanged drug; biliary/fecal (5-10%).
Approximately 50–70% bound to albumin.
20-25% bound to albumin.
Vd: 0.25–0.35 L/kg; clinical meaning: indicates distribution primarily into extracellular fluid, with limited tissue penetration.
0.5-0.8 L/kg; indicates distribution into total body water.
Oral: 85–100% (well absorbed from gastrointestinal tract).
Oral: 90-100% (well absorbed).
Cr Cl 10-50 m L/min: administer every 8-12 hours. Cr Cl <10 m L/min: administer every 12-24 hours. Avoid use in severe renal impairment.
Cr Cl 10-50 m L/min: 250 mg every 6 hours. Cr Cl <10 m L/min: 250 mg every 12 hours.
Child-Pugh Class A: no adjustment. Child-Pugh Class B or C: avoid use due to potential accumulation and hepatotoxicity.
Child-Pugh Class C: avoid use; Class A or B: no adjustment needed.
Not recommended for children due to risk of kernicterus and adverse effects; safety not established.
10-15 mg/kg orally every 6 hours; maximum 100 mg/kg/day.
Start at lower end of dosing range; monitor renal function and for adverse effects; increased risk of sulfonamide-induced reactions.
Consider dose reduction based on renal function; initial dose not to exceed 2 g per day.
None.
Sulfonamides have been associated with fatal reactions such as Stevens-Johnson syndrome, toxic epidermal necrolysis, agranulocytosis, aplastic anemia, and other blood dyscrasias.
Severe hypersensitivity reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), hematologic toxicity (agranulocytosis, hemolytic anemia in G6PD deficiency), hepatotoxicity, renal toxicity. Discontinue if rash or signs of hypersensitivity.
Increased risk of hypersensitivity reactions (SJS, TEN); hematologic toxicity (agranulocytosis, thrombocytopenia); hepatotoxicity; renal toxicity due to crystalluria; hemolytic anemia in G6PD-deficient patients; photosensitivity.
Hypersensitivity to sulfonamides, porphyria, severe hepatic or renal impairment, pregnancy (especially near term) and lactation, infants <2 months (except for congenital toxoplasmosis).
Hypersensitivity to sulfonamides or trimethoprim; severe hepatic or renal impairment; megaloblastic anemia due to folate deficiency; pregnancy (especially first trimester and near term); lactation; pediatric patients <2 months of age.
No specific food interactions. Avoid alcohol as it may increase risk of adverse effects like disulfiram-like reaction. Ensure adequate hydration with water; acidic foods do not significantly affect absorption.
No significant food interactions known. No dietary restrictions required.
First trimester: Sulfapyridine, a sulfonamide, crosses the placenta. There is a potential risk of neural tube defects and other malformations based on animal studies, but human data are limited. Second and third trimesters: Sulfonamides compete with bilirubin for albumin binding, increasing the risk of kernicterus in the neonate if administered near term. Use is generally avoided after 32 weeks gestation.
Pregnancy category C. First trimester: Potential risk of neural tube defects based on animal studies. Second and third trimesters: Increased risk of premature closure of ductus arteriosus and oligohydramnios due to prostaglandin synthesis inhibition. Limited human data; avoid unless benefit outweighs risk.
Sulfapyridine is excreted into breast milk. The milk-to-plasma (M/P) ratio is approximately 0.45. Low levels are unlikely to cause adverse effects in healthy term infants, but caution is advised in premature, ill, or G6PD-deficient infants due to potential for hemolysis or kernicterus.
Excreted in breast milk in low quantities. M/P ratio not established. Potential risk of adverse effects in nursing infants (e.g., renal dysfunction, bleeding). Use with caution if alternative therapies are not available.
No specific dose adjustments are recommended, but pharmacokinetic changes in pregnancy (increased volume of distribution and renal clearance) may reduce drug levels. Monitor therapeutic response and consider adjusting dose based on clinical indication and serum levels if available.
No standard dosing adjustment during pregnancy. Increased renal clearance and volume of distribution in pregnancy may reduce efficacy; consider dose titration based on clinical response. Avoid in third trimester if possible.
Sulfapyridine is primarily used for dermatitis herpetiformis (DH). Dose adjustments needed in renal impairment. Monitor for hypersensitivity reactions, hemolytic anemia in G6PD deficiency, and crystalluria. Increase fluid intake to 2-3 L/day to prevent renal toxicity. Not first-line for other infections due to resistance.
Cetamide (sulfacetamide sodium) is a topical ophthalmic sulfonamide used for bacterial conjunctivitis. Monitor for hypersensitivity, as cross-allergy with other sulfonamides may occur. Use with caution in patients with dry eye syndrome or corneal abrasions. Avoid prolonged use to prevent superinfection. Administer with clean hands and do not touch dropper tip to any surface.
Take with a full glass of water and maintain high fluid intake to prevent kidney stones.,Avoid prolonged sun exposure and use sunscreen, as sulfonamides can cause photosensitivity.,Report any skin rash, fever, sore throat, or unusual bleeding immediately.,Complete full course as prescribed, but do not use for viral infections.,Inform doctor if pregnant, breastfeeding, or have glucose-6-phosphate dehydrogenase deficiency.
Wash hands before and after applying the eye drops.,Do not touch the dropper tip to your eye or any other surface.,Wait 5 minutes between different eye drops if using more than one type.,Complete the full course of treatment even if symptoms improve.,Do not wear contact lenses during treatment unless directed by your doctor.,Stop use and contact your doctor if you experience rash, itching, or swelling.,Keep the bottle tightly closed when not in use and store at room temperature.
"Sulfacetamide may reduce the efficacy of picosulfuric acid, a stimulant laxative, through antibiotic-mediated disruption of the gut microbiota. The conversion of picosulfate to its active metabolite, BHPM, relies on bacterial azoreductase enzymes in the colon. Sulfacetamide's antibacterial activity against colonic flora can decrease this bioactivation, leading to diminished laxative effect and potential treatment failure for constipation or bowel preparation."
"The risk or severity of adverse effects can be increased when Methenamine is combined with Sulfacetamide."
"The risk or severity of adverse effects can be increased when Sulfacetamide is combined with Mecamylamine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SULFAPYRIDINE vs CETAMIDE, answered by our medical review team.
SULFAPYRIDINE is a Sulfonamide Antibiotic that works by Sulfapyridine is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, blocking folate synthesis and thereby nucleic acid production. It also has anti-inflammatory and immunomodulatory effects in dermatologic conditions through unknown mechanisms.. CETAMIDE is a Sulfonamide antibiotic that works by CETAMIDE is an antimicrobial combination of sulfadiazine (a sulfonamide) and trimethoprim. Sulfonamides inhibit dihydropteroate synthase, blocking folate synthesis; trimethoprim inhibits dihydrofolate reductase, producing sequential blockade of folic acid metabolism.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SULFAPYRIDINE and CETAMIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SULFAPYRIDINE is: 500 mg orally four times daily for initial treatment of dermatitis herpetiformis; maintenance dose 500 mg daily to 1.5 g daily in divided doses.. The standard adult dose of CETAMIDE is: 500 mg orally every 6 hours; maximum 4 g per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SULFAPYRIDINE and CETAMIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SULFAPYRIDINE is classified as Category C. First trimester: Sulfapyridine, a sulfonamide, crosses the placenta. There is a potential risk of neural tube defects and other malformations based on animal studies, but human dat. CETAMIDE is classified as Category C. Pregnancy category C. First trimester: Potential risk of neural tube defects based on animal studies. Second and third trimesters: Increased risk of premature closure of ductus art. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.